Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

UPDATED: Indications Table for BCMA and CD19 CAR-Ts US Approvals and Submissions

Here is a brief preview of this blast: New content: The Celltelligence team has created a BCMA CAR-T indications table for estimated US approvals and submissions following key Q2 2022 earnings presentations and recent press releases (see below for download). Of note, no updates were observed in Celltelligence’s CD19 CAR-T indications table.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.